Aptevo Therapeutics’ Bispecific Antibody APVO436 Shows Robust T-Cell Activation With Minimal Cytokine Release

World News: . []

SEATTLE April 16 2018 GLOBE NEWSWIRE -- Aptevo Therapeutics Inc NasdaqAPVO a biotechnology company focused on developing novel oncology and hematology therapeutics today announced the presentation of new data for APVO436 a bispecific an tibody ...

More news and information about Aptevo Therapeutics Inc.

Published By:

Globe Newswire: 14:02 GMT Monday 16th April 2018

Published: .

Search for other references to "aptevo" on SPi News


Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 0751938.
Privacy Policy | Terms and Conditions | Contact Us